Lucy小影
Lv4
610 积分
2023-07-12 加入
-
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
23天前
已完结
-
Accelerating Global Deletion of the Abnormal Toxicity Test for vaccines and biologicals. Planning common next steps. A workshop Report
2个月前
已完结
-
Process Validation in Manufacturing of Biopharmaceuticals
2个月前
已完结
-
Subvisible Particulate Matter in Therapeutic Protein Injections
3个月前
已完结
-
Body of evidence and approaches applied in the clinical development programme of fixed‐dose combinations in the European Union from 2010 to 2016
4个月前
已完结
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
-
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
4个月前
已完结
-
Fixed Dosing of Monoclonal Antibodies in Oncology
4个月前
已完结
-
Fixed dose combinations: A formulary decision guide
4个月前
已完结
-
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies
4个月前
已完结